NYSE · CHE
Healthcare · Medical - Care Facilities
$500.77
Up+$12.41 (+2.48%)
Updated Oct 15, 2026, 1:11 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CHE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
CHE closed at $500.77 after 20 trading sessions, down 1.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $504.83 | $505.89 | $496.79 | $500.77 | 104.63K |
| Oct 12, 2026 | $501.76 | $505.87 | $499.57 | $500.64 | 119.7K |
| Oct 9, 2026 | $497.65 | $502.1475 | $493.43 | $499.82 | 134.46K |
| Oct 8, 2026 | $495.65 | $499.73 | $494.12 | $498.25 | 135.45K |
| Oct 7, 2026 | $508.32 | $514.67 | $499.52 | $501.45 | 139.13K |
| Oct 6, 2026 | $513.77 | $517.98 | $506.32 | $509.84 | 129.21K |
| Oct 5, 2026 | $505.75 | $514.455 | $500.97 | $511.30 | 139.77K |
| Oct 2, 2026 | $502.88 | $510.82 | $499.64 | $507.50 | 159.12K |
| Oct 1, 2026 | $504.91 | $508.35 | $497.2875 | $502.90 | 201.69K |
| Sep 30, 2026 | $512.16 | $514.50 | $503.36 | $505.07 | 155.94K |
| Sep 29, 2026 | $511.34 | $516.815 | $507.47 | $512.05 | 118.31K |
| Sep 28, 2026 | $512.15 | $519.045 | $509.105 | $514.30 | 216K |
| Sep 25, 2026 | $503.12 | $514.51 | $498.79 | $512.16 | 233.29K |
| Sep 24, 2026 | $499.19 | $501.46 | $491.875 | $495.65 | 146.21K |
| Sep 23, 2026 | $494.97 | $505.215 | $493.98 | $498.09 | 138.54K |
| Sep 22, 2026 | $500.55 | $505.79 | $495.37 | $496.62 | 132.26K |
| Sep 21, 2026 | $507.79 | $509.59 | $496.97 | $499.62 | 159.28K |
| Sep 18, 2026 | $504.50 | $512.25 | $498.23 | $504.06 | 417.57K |
| Sep 17, 2026 | $509.06 | $516.88 | $500.52 | $505.97 | 144.67K |
| Sep 16, 2026 | $506.75 | $513.5425 | $500.935 | $509.91 | 141.08K |
The latest Smart Investors Daily articles mentioning CHE.
Company
Market Activity
Research & News
CHE research
Company profile and research snapshot.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | UBS | Buy | — |
| Jul 31, 2026 | Oppenheimer | Outperform | — |
| Jul 30, 2026 | RBC Capital | Sector Perform | — |
| Jul 9, 2026 | B of A Securities | Neutral | — |
| Apr 27, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Oct 9, 2026
Over the past six months, Chemed has been a great trade, beating the S&P 500 by 11.9%. Its stock price has climbed to $493.23, representing a healthy 26.2% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · Oct 1, 2026
CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, October 28, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the c
Yahoo · Oct 1, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Yahoo · Sep 26, 2026
Chemed has logged a 20.9% gain year to date, which puts a spotlight on whether the current share price lines up with the cash the business is expected to generate. With investors weighing both its healthcare hospice operations and its Roto-Rooter services arm, the central issue is what that mix of businesses is really worth when you focus on its cash flows. The stock is up 20.9% year to date, so anyone looking at Chemed today is effectively asking if that move already reflects the cash the...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CHE.
